Diabetes
Onglyza, a New Type 2 Diabetes Drug Approved by FDA
The U.S. Food and Drug Administration (FDA) today approved Onglyza (saxagliptin), a once-daily tablet to treat Type 2 diabetes in adults. The medication is intended to be used with diet and exercise to control high blood sugar levels. The hormone insulin keeps blood sugar (glucose) levels within a narrow range in people who don’t have... »
Higher Levels of adiponectin Protein Associated with Lower Risk of Type 2 Diabetes
Persons with higher levels of adiponectin, a protein that is produced by fat cells and that has anti-inflammatory and insulin-sensitizing properties, have an associated lower risk of type 2 diabetes, according to an analysis of previous studies, reported in the July 8 issue of JAMA. Some studies have suggested several mechanisms through which adiponectin may... »
BMP-7 Protein Produces “Good” Fat that Helps Fight Obesity
Researchers have found that a bone growth protein, known as BMP-7, also aids the growth of brown (or "good") fat that helps fight obesity. "Obesity is occurring at epidemic rates in the U.S. and worldwide and that impacts the risk and prognosis of many diseases," said Yu-Hua Tseng, Ph.D. an Assistant Investigator... »
Risk of Type 1 Diabetes in Children Related to Vitamin D and Sun
Researchers have found that the risk of Type 1 diabetes in children may be strongly associated with Vitamin D and exposure to sunshine. Low incidence of type 1 diabetes was noted in people living in equatorial regions, while higher incidence was noted in populations at higher latitudes where sunlight was scarcer. »
FDA Warns of Cancer Risk for Regranex in Treatment of Diabetics’ Foot and Leg Ulcers
The U.S. Food and Drug Administration (FDA) has announced the addition of a boxed warning to the label of Regranex Gel 0.01% (becaplermin) to address the increased risk of cancer mortality in patients who use 3 or more tubes of the product. Regranex is a topical cream indicated for the treatment of leg and... »
Gene Linked to Severe Diabetic Retinopathy and Renal Disease
Researchers have identified a gene called erythropoietin (EPO) that is linked to higher risk of severe retinopathy and nephropathy, eye and kidney diseases that often affect diabetic patients. Diabetic retinopathy (PDR) is the most common cause of legal blindness in working-aged adults in the United States, accounting for 10% of new cases of blindness. Diabetes... »
Higher Fracture Risk for Diabetes Drugs Such as Pioglitazone and Rosiglitazone, Says Study
Insulin-sensitizing thiazolidinediones, such as pioglitazone and rosiglitazone, appear to be associated with an increased risk of fractures, according to a recent report. These two drugs account for about 21% of oral diabetes medications prescribed in the United States, and 5% of those prescribed in Europe. »
Insulin Research May Lead to Longer, Healthier Life
Insulin can affect aging and lifespan, a previously unknown outcome which could provide a means of gene manipulation capable of lengthening lives and making people healthier. »
Not Enough Doctors to Treat Increasing Number of Obese and Diabetic Children
The number of diabetic and obese children is growing so rapidly that there aren't enough doctors to treat the kids. According to a recent study by University of Michigan's C.S. Mott Hospital, there is only one board-certified pediatric endocrinologist per 290 children with diabetes. The ratio of obese children to board-certified endocrinologists... »
Burnham Institute for Medical Research Appoints Daniel P. Kelly, M.D. as Scientific Director for Florida Campus
Burnham Institute for Medical Research (Burnham) today announced that Daniel P. Kelly, M.D. will assume the position of Scientific Director of Burnham at Lake Nona in Orlando, Florida. »